Cargando…
Disclosure of preclinical Alzheimer's disease biomarker results in research and clinical settings: Why, how, and what we still need to know
Disclosure of personal disease‐related information to asymptomatic adults has been debated over the last century in medicine and research. Recently, Alzheimer's disease (AD) has been conceptualized as a continuum that begins with a “preclinical” stage in which biomarkers are present in the abse...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896633/ https://www.ncbi.nlm.nih.gov/pubmed/33665341 http://dx.doi.org/10.1002/dad2.12150 |
_version_ | 1783653576501886976 |
---|---|
author | Erickson, Claire M. Chin, Nathaniel A. Johnson, Sterling C. Gleason, Carey E. Clark, Lindsay R. |
author_facet | Erickson, Claire M. Chin, Nathaniel A. Johnson, Sterling C. Gleason, Carey E. Clark, Lindsay R. |
author_sort | Erickson, Claire M. |
collection | PubMed |
description | Disclosure of personal disease‐related information to asymptomatic adults has been debated over the last century in medicine and research. Recently, Alzheimer's disease (AD) has been conceptualized as a continuum that begins with a “preclinical” stage in which biomarkers are present in the absence of cognitive impairment. Studies have begun assessing the safety, psychological, and behavioral effects of disclosing both AD‐related genetic and biomarker information to cognitively unimpaired older adults. Yet, debate continues over the appropriate circumstances and methods for returning such information. This article outlines concerns with and rationale for AD biomarker disclosure and summarizes findings from prior studies. Overall, this article aims to describe and respond to key questions concerning disclosure of amyloid positron emission tomography scan results to asymptomatic adults in a research setting. Moving forward, such conditions are important to consider as interventions target the preclinical phase of AD and normalize disclosing biomarker information to cognitively unimpaired persons. |
format | Online Article Text |
id | pubmed-7896633 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78966332021-03-03 Disclosure of preclinical Alzheimer's disease biomarker results in research and clinical settings: Why, how, and what we still need to know Erickson, Claire M. Chin, Nathaniel A. Johnson, Sterling C. Gleason, Carey E. Clark, Lindsay R. Alzheimers Dement (Amst) Diagnostic Assessment & Prognosis Disclosure of personal disease‐related information to asymptomatic adults has been debated over the last century in medicine and research. Recently, Alzheimer's disease (AD) has been conceptualized as a continuum that begins with a “preclinical” stage in which biomarkers are present in the absence of cognitive impairment. Studies have begun assessing the safety, psychological, and behavioral effects of disclosing both AD‐related genetic and biomarker information to cognitively unimpaired older adults. Yet, debate continues over the appropriate circumstances and methods for returning such information. This article outlines concerns with and rationale for AD biomarker disclosure and summarizes findings from prior studies. Overall, this article aims to describe and respond to key questions concerning disclosure of amyloid positron emission tomography scan results to asymptomatic adults in a research setting. Moving forward, such conditions are important to consider as interventions target the preclinical phase of AD and normalize disclosing biomarker information to cognitively unimpaired persons. John Wiley and Sons Inc. 2021-02-20 /pmc/articles/PMC7896633/ /pubmed/33665341 http://dx.doi.org/10.1002/dad2.12150 Text en © 2021 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Diagnostic Assessment & Prognosis Erickson, Claire M. Chin, Nathaniel A. Johnson, Sterling C. Gleason, Carey E. Clark, Lindsay R. Disclosure of preclinical Alzheimer's disease biomarker results in research and clinical settings: Why, how, and what we still need to know |
title | Disclosure of preclinical Alzheimer's disease biomarker results in research and clinical settings: Why, how, and what we still need to know |
title_full | Disclosure of preclinical Alzheimer's disease biomarker results in research and clinical settings: Why, how, and what we still need to know |
title_fullStr | Disclosure of preclinical Alzheimer's disease biomarker results in research and clinical settings: Why, how, and what we still need to know |
title_full_unstemmed | Disclosure of preclinical Alzheimer's disease biomarker results in research and clinical settings: Why, how, and what we still need to know |
title_short | Disclosure of preclinical Alzheimer's disease biomarker results in research and clinical settings: Why, how, and what we still need to know |
title_sort | disclosure of preclinical alzheimer's disease biomarker results in research and clinical settings: why, how, and what we still need to know |
topic | Diagnostic Assessment & Prognosis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7896633/ https://www.ncbi.nlm.nih.gov/pubmed/33665341 http://dx.doi.org/10.1002/dad2.12150 |
work_keys_str_mv | AT ericksonclairem disclosureofpreclinicalalzheimersdiseasebiomarkerresultsinresearchandclinicalsettingswhyhowandwhatwestillneedtoknow AT chinnathaniela disclosureofpreclinicalalzheimersdiseasebiomarkerresultsinresearchandclinicalsettingswhyhowandwhatwestillneedtoknow AT johnsonsterlingc disclosureofpreclinicalalzheimersdiseasebiomarkerresultsinresearchandclinicalsettingswhyhowandwhatwestillneedtoknow AT gleasoncareye disclosureofpreclinicalalzheimersdiseasebiomarkerresultsinresearchandclinicalsettingswhyhowandwhatwestillneedtoknow AT clarklindsayr disclosureofpreclinicalalzheimersdiseasebiomarkerresultsinresearchandclinicalsettingswhyhowandwhatwestillneedtoknow |